Quipt Home Medical (QIPT – Research Report), the Healthcare company, has received a rating update from a Wall Street analyst today. Analyst Justin Keywood from Stifel Nicolaus reiterated a Buy rating
Keywood has an average return of 17.2% when recommending Quipt Home Medical.
According to TipRanks.com, Keywood is ranked #4392 out of 8561 analysts.
Currently, the analyst consensus on Quipt Home Medical is a Strong Buy with an average price target of C$13.37.
Quipt Home Medical’s market cap is currently C$316.4M and has a P/E ratio of 494.74.
Protech Home Medical Corp provides in-home monitoring equipment, supplies and services to patients. The company’s services consist of Daily & Ambulatory Aides, Power Mobility, INR Self-Testing, Respiratory Equipment Rental, Home ventilation, Oxygen Therapy, and Sleep Apnea & PAP Treatment.
The company’s shares closed last Friday at C$7.52.
Read More on TSE:QIPT:
- Quipt Announces Multi-State Acquisition Adding Approximately $9 Million in Annualized Revenues, and Anticipated $2 Million in Adjusted EBITDA Post Integration
- Quipt Home Medical reports Q2 revenue $60.3M, consensus $60.03M
- Quipt Home Medical Reports Strong Operational Performance With Record Third Quarter Fiscal 2023 Financial Results Posting Revenue Growth of 64% and Adjusted EBITDA Growth of 80%
- Is QIPT a Buy, Before Earnings?
- Quipt Home Medical to Participate at the 43rd Annual Canaccord Growth Conference
